Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia (CARE-HK)
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia (CARE-HK in HF Registry)
Sponsor: Vifor (International) Inc.
A observational or N/A phase clinical study on Heart Failure and Hyperkalemia, this trial is completed. The trial is conducted by Vifor (International) Inc. and has accumulated 12 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Dec 2024 — Sep 2025 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2024 — May 2024 [monthly]
Recruiting
-
Mar 2023 — Jan 2024 [monthly]
Recruiting
-
Jul 2022 — Mar 2023 [monthly]
Recruiting
-
Nov 2021 — Jul 2022 [monthly]
Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting
-
May 2021 — Jun 2021 [monthly]
Recruiting
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vifor (International) Inc.
For direct contact, visit the study record on ClinicalTrials.gov .